Medics Autonomously Stopping Hemorrhage (MASH)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
The Defense Advanced Research Projects Agency (DARPA) is soliciting proposals to develop demonstrator autonomous systems to stabilize torso hemorrhage without need of a surgeon in forward medical sites, providing 48+ hours to reach definitive care. The Medics Autonomously Stopping Hemorrhage (MASH) program is seeking approaches that merge multi-modal automated bleed detection and localization with automated, minimally invasive robotic end effectors and sensors. MASH’s vision is to push the standard of pre-hospital hemorrhage control to 48 hours; stop lethal forms of torso hemorrhage without a surgeon; and provide minimally invasive surgery (MIS) a path to enter the trauma market and utilize full autonomy.